Development
Soligenix’s HyBryte shows improved response and tolerability vs Valchlor in small CTCL study
Soligenix (Nasdaq: SNGX) reported that a small comparative study of synthetic hypericin (HyBryte) versus mechlorethamine (Valchlor) in cutaneous T-cell...
Oric's PRC2 inhibitor rinzimetostat combo regimen advances to Phase III trial in mCRPC
ORIC Pharmaceuticals (Nasdaq: ORIC) reported Phase Ib dose optimization data for rinzimetostat in combination with darolutamide in post-abiraterone...
Novo Nordisk follows Lilly's oral GLP-1 approval with data showing Wegovy's weight loss advantage
Novo Nordisk (NVO) reported that oral semaglutide 25 mg (Wegovy) produced approximately 3 percentage points more weight loss than orforglipron in a...
Alto discontinues transdermal PDE4 inhibitor after Phase II failure in schizophrenia-linked cognitive impairment
Alto Neuroscience (NYSE: ANRO) reported that ALTO-101 failed to meet its primary EEG or cognitive endpoints versus placebo in a Phase II proof-of-concept...
Gan & Lee's once-weekly basal insulin beats insulin glargine and degludec in Phase III type 2 diabetes trials
Gan & Lee Pharmaceuticals (SSE: 603087) reported that its investigational once-weekly basal insulin analog, GZR4, met the primary endpoint of superior HbA1c...
Enveda's oral atopic dermatitis candidate shows 85% EASI reduction in early trial
Enveda, the Boulder, Colo.-based biotechnology company, reported Phase 1b results for ENV-294 in moderate-to-severe atopic dermatitis, with interim findings...
CSPC’s HER2 bispecific anbenitamab's Phase III challenges neoadjuvant breast cancer standard
CSPC Pharmaceutical Group (HKEX: 01093) announced on March 31 that anbenitamab (KN026), a HER2 bispecific antibody, met its pre-specified primary endpoint...
AstraZeneca's efzimfotase alfa posts mixed Phase III results for pediatric hypophosphatasia
Alexion, AstraZeneca's (LSE/STO/NYSE: AZN) rare disease unit, reported positive results from a three-trial Phase III programme for efzimfotase alfa in...
Takeda's zasocitinib aces Phase III in moderate-to-severe plaque psoriasis trials
Takeda (TSE:4502/NYSE:TAK) reported that zasocitinib, its investigational oral TYK2 inhibitor, met co-primary endpoints in two Phase III trials in adults...
BridgeBio's acoramidis shows sustained mortality reduction in 54-month ATTR-CM extension study
BridgeBio Pharma (Nasdaq: BBIO) reported 54-month open-label extension data for acoramidis (Attruby) in ATTR-CM showing a 44.7% reduction in all-cause...
Hengrui, Braveheart's cardiac myosin inhibitor shows stronng early efficacy against cardiomyopathy
Hengrui Pharma and Braveheart Bio reported Phase 2 results for HRS-1893 (BHB-1893), a selective small-molecule cardiac myosin inhibitor, in patients with...
Viridian Therapeutics' elegrobart meets primary endpoint in Phase III active thyroid eye disease trial
Viridian Therapeutics (Nasdaq: VRDN) reported Phase III data from the REVEAL-1 trial showing that elegrobart, a subcutaneous anti-IGF-1R monoclonal...
United Therapeutics' Tyvaso meets primary endpoint in Phase III for IPF
United Therapeutics (Nasdaq: UTHR) reported that treprostinil inhalation solution (Tyvaso) met the primary endpoint in the TETON-1 Phase III trial for...
Biogen's litifilimab meets Phase II endpoint in cutaneous lupus erythematosus trial
Biogen (Cambridge, Mass.) reported that litifilimab met the primary endpoint in the Phase II portion of the AMETHYST Phase II/III trial in cutaneous lupus...
Delonix takes engineered outer membrane vesicle meningitis vaccine into first-in-human trial in Australia
Delonix Bioworks, a clinical-stage biotechnology company based in Shanghai and Perth, has initiated first-in-human dosing of the DX-104 vaccine, a MenB OMV...
The AllSci Brief
Systematic R&D and deal news. Daily.